Medical management of Parkinson's disease.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it.

1. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications.The Cochrane database of systematic reviews · 2010
   Pooled it
2. Dopamine agonist therapy in early Parkinson's disease.The Cochrane database of systematic reviews · 2008
   Pooled it
3. Computational Repurposing of Nilotinib and Radotinib as SIRT2 Inhibitors for Neurodegenerative Diseases.Journal of molecular neuroscience : MN · 2026
   Article
4. Parkinson's Disease: Current Treatment Modalities and Emerging Therapies.Cureus · 2024
   Review
5. Distribution of Cleaved SNAP-25 in the Rat Brain, following Unilateral Injection of Botulinum Neurotoxin-A into the Striatum.International journal of molecular sciences · 2023
   Article
6. Dopamine Deficiency Reduces Striatal Cholinergic Interneuron Function in Models of Parkinson's Disease.Neuron · 2019
   Article
7. Repeated Intrastriatal Botulinum Neurotoxin-A Injection in Hemiparkinsonian Rats Increased the Beneficial Effect on Rotational Behavior.Toxins · 2018
   Article
8. Unilateral Botulinum Neurotoxin-A Injection into the Striatum of C57BL/6 Mice Leads to a Different Motor Behavior Compared with Rats.Toxins · 2018
   Article
9. Experimental Intrastriatal Applications of Botulinum Neurotoxin-A: A Review.International journal of molecular sciences · 2018
   Review
10. Botulinum Neurotoxin A Injected Ipsilaterally or Contralaterally into the Striatum in the Rat 6-OHDA Model of Unilateral Parkinson's Disease Differently Affects Behavior.Frontiers in behavioral neuroscience · 2017
    Article
11. A Comparative Pharmacokinetics Study of the Anti-Parkinsonian Drug Pramipexole.Scientia pharmaceutica · 2016
    Article
12. The cholinergic system and Parkinson disease.Behavioural brain research · 2011
    Review
13. Medical management of Parkinson's disease: focus on neuroprotection.Current neuropharmacology · 2011
    Article
14. Acetylcholine-dopamine interactions in the pathophysiology and treatment of CNS disorders.CNS neuroscience & therapeutics · 2010
    Review
15. Potential cellular and regenerative approaches for the treatment of Parkinson's disease.Neuropsychiatric disease and treatment · 2008
    Article
16. M1 muscarinic receptors contribute to, whereas M4 receptors inhibit, dopamine D1 receptor-induced [3H]-cyclic AMP accumulation in rat striatal slices.Neurochemical research · 2006
    Article
17. Treatment benefit and daily drug costs associated with treating Parkinson's disease in a Parkinson's disease clinic.CNS drugs · 2004
    Article
18. Evaluating drug treatments for Parkinson's disease: how good are the trials?BMJ (Clinical research ed.) · 2002
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as